文摘
摘要目的:确定颞肌酸酐的模式和c反应蛋白的诊断前后肌萎缩性脊髓侧索硬化症,多发性硬化症和帕金森氏病。
背景:血清肌酐和c反应蛋白已经被提议作为神经退行性疾病的潜在生物标志物。然而,纵向研究调查时间模式的这些生物标记,包括诊断前的阶段,是罕见的。
设计/方法:我们进行了病例对照研究包括所有新诊断患者的肌萎缩性脊髓侧索硬化症(N = 525),多发性硬化症(N = 1815)、或帕金森病(N = 3797)在2006 - 2013年在斯德哥尔摩,瑞典,斯德哥尔摩参加肌酐测量项目。针对每种情况,五控制被年龄,分别随机选择和匹配性,和居住的县(N = 2625肌萎缩性脊髓侧索硬化症,多发性硬化症N = 9063,和18960年帕金森病)。我们收集测试结果血清肌酐和c反应蛋白的所有个人和可视化中肌酐水平和c反应蛋白的使用案例之间的局部加权平滑曲线和控制。线性混合模型也适用于探索时间的变化在一个独立的个体。
结果:控制相比,肌萎缩性脊髓侧索硬化症患者的肌酐水平较低从两年前开始诊断。相比之下,肌萎缩性脊髓侧索硬化症患者c反应蛋白水平较低诊断但更高层次诊断之前,而控制。肌萎缩性脊髓侧索硬化症患者显示统计上显著降低肌酐水平从诊断前一年到两年之后诊断,而增加的c反应蛋白水平从诊断到两年后的诊断。没有类似的模式指出在多发性硬化症患者或帕金森症,或三个病人组的控制。
结论:肌萎缩性脊髓侧索硬化症患者显示不同的颞肌酸酐的模式和c反应蛋白诊断、前后相比,肌萎缩性脊髓侧索sclerosis-free控制或多发性硬化症患者和帕金森病。
披露:崔没有披露。孙先生没有披露。Yudi Pawitan没有披露。圣博士已经收到个人薪酬在5000 - 9999美元的范围为在科学咨询服务或数据安全监测委员会Parexel / Chugai。圣博士的机构已收到支持的联合研究。圣博士的机构已经收到了来自默克公司的研究支持。圣博士已经收到个人薪酬在10000 - 49999美元的范围作为科学顾问委员会成员与瑞典的医疗产品。陈竺的机构收到NIH的研究支持,。陈竺的机构已经收到了来自国防部的研究支持。陈竺的机构已收到研究帕金森基金会的支持。 The institution of Dr. Chen has received research support from MSU GE and Gibby vs. Parky project. Ingre Ingre has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. The institution of Ingre Ingre has received research support from Ulla Carin Lindqvist . The institution of Dr. Wirdefeldt has received research support from The Parkinson Foundation in Sweden. The institution of Dr. Wirdefeldt has received research support from Swedish Research Council. Marie Evans has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astellas. Marie Evans has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vifor Pharma. Marie Evans has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astellas. Marie Evans has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra Zeneca. Marie Evans has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vifor Pharma. Marie Evans has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Swedish Renal Registry. John Andersson has nothing to disclose. Juan-Jesus Carrero has nothing to disclose. Fang Fang has nothing to disclose.
